Document is current
Any future updates will be listed below
-
Authors
Amengual, Josep
Alay, Ania https://orcid.org/0000-0002-5090-2913
Vaquero, Javier https://orcid.org/0000-0002-6020-6962
Gonzalez-Sanchez, Ester
Bertran, Esther
Sánchez, Aránzazu
Herrera, Blanca
Meyer, Kathleen
Maus, Mate https://orcid.org/0000-0002-2128-2479
Serrano, Manuel https://orcid.org/0000-0001-7177-9312
Martínez-Chantar, María Luz https://orcid.org/0000-0002-6446-9911
Fabregat, Isabel https://orcid.org/0000-0003-0136-8440
- License Information
-
More Information
Article History
Received: 6 May 2024
Revised: 3 September 2024
Accepted: 6 September 2024
First Online: 17 September 2024
Competing interests
: MS is shareholder of Senolytic Therapeutics, Inc., Life Biosciences, Inc., Rejuveron Senescence Therapeutics, AG, and Altos Labs, Inc.
: The procedure complied with the EU Directive 2010/63/UE for animal experiments and the institution’s guidelines and was approved by the General Direction of Environment and Biodiversity, Government of Catalonia (#4589) and the Ethical Committee for Animal Experimentation at IDIBELL, with the number EST-FOR-90.01. We have followed the 3R recommendations: Replacement, Reduction and Refinement.
